CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:SEETrials: Leveraging large language models for safety and efficacy extraction in oncology clinical trials.
SEETrials: Leveraging large language models for safety and efficacy extraction in oncology clinical trials.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
SEETrials 展现出高度准确的数据提取能力,并在不同治疗药物和多种癌症领域具有通用性。
肿瘤临床试验结果的初步信息通常需从会议摘要中人工提取。我们旨在开发一套自动化系统,以高精度和精细粒度从研究摘要中提取安全性和疗效信息,并将其转化为可计算数据,支持及时的临床决策。
我们收集2012至2023年主要学术会议和PubMed收录的临床试验摘要。SEETrials系统由三个模块组成:预处理、结合知识摄取的提示工程,以及后处理。我们对系统性能进行定性和定量评估,并评估其在多种癌症类型中的泛化能力,包括多发性骨髓瘤(MM)、乳腺癌、肺癌、淋巴瘤和白血病。此外,我们基于大量临床试验研究分析MM创新疗法(包括CAR-T、双特异性抗体和抗体药物偶联物〔ADC〕)的疗效和安全性。
在MM试验研究的70项数据要素中,SEETrials取得较高的精确率(0.964)、召回率(敏感度,0.988)和F1分数(0.974)。在另外四种癌症中的泛化测试得到0.979至0.992的精确率、召回率和F1分数。不同疗法的安全性和疗效相关实体分布存在差异,某些不良事件在特定治疗中更常见。采用总缓解率(ORR)和完全缓解(CR)进行比较,显示不同疗法之间存在差异:CAR-T(ORR:88%,95% CI:84%–92%;CR:95%,95% CI:53%–66%)、双特异性抗体(ORR:64%,95% CI:55%–73%;CR:27%,95% CI:16%–37%)以及ADC(ORR:51%,95% CI:37%–65%;CR:26%,95% CI:1%–51%)。在若干治疗亚组中分析的多个结局实体存在显著研究异质性(I²异质性指数均>75%)。
SEETrials实现了高精度的数据提取,并可灵活用于不同疗法和癌症领域。该系统自动处理大型数据集,有助于细致比较数据,促进临床见解快速、有效地传播。
Initial insights into oncology clinical trial outcomes are often gleaned manually from conference abstracts. We aimed to develop an automated system to extract safety and efficacy information from study abstracts with high precision and fine granularity, transforming them into computable data for timely clinical decision-making.
We collected clinical trial abstracts from key conferences and PubMed (2012-2023). The SEETrials system was developed with three modules: preprocessing, prompt engineering with knowledge ingestion, and postprocessing. We evaluated the system's performance qualitatively and quantitatively and assessed its generalizability across different cancer types- multiple myeloma (MM), breast, lung, lymphoma, and leukemia. Furthermore, the efficacy and safety of innovative therapies, including CAR-T, bispecific antibodies, and antibody-drug conjugates (ADC), in MM were analyzed across a large scale of clinical trial studies.
SEETrials achieved high precision (0.964), recall (sensitivity) (0.988), and F1 score (0.974) across 70 data elements present in the MM trial studies Generalizability tests on four additional cancers yielded precision, recall, and F1 scores within the 0.979-0.992 range. Variation in the distribution of safety and efficacy-related entities was observed across diverse therapies, with certain adverse events more common in specific treatments. Comparative performance analysis using overall response rate (ORR) and complete response (CR) highlighted differences among therapies: CAR-T (ORR: 88 %, 95 % CI: 84-92 %; CR: 95 %, 95 % CI: 53-66 %), bispecific antibodies (ORR: 64 %, 95 % CI: 55-73 %; CR: 27 %, 95 % CI: 16-37 %), and ADC (ORR: 51 %, 95 % CI: 37-65 %; CR: 26 %, 95 % CI: 1-51 %). Notable study heterogeneity was identified (>75 % I 2 heterogeneity index scores) across several outcome entities analyzed within therapy subgroups.
SEETrials demonstrated highly accurate data extraction and versatility across different therapeutics and various cancer domains. Its automated processing of large datasets facilitates nuanced data comparisons, promoting the swift and effective dissemination of clinical insights.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。